Low-grade systemic inflammation (hsCRP 2–10 mg/L) stratified risk beyond comorbidities and medications in both CKD+ASCVD and ...
Standard-of-care therapies for metastatic renal cell carcinoma (mRCC) have greatly evolved. However, the availability of emerging options in global health care systems can vary. We sought to describe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results